{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-032021","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.227792+00:00","generated_at":"2026-06-10T21:00:26.883859+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avalo sells 800 series assets to AUG for $150K upfront, up to $45M in milestones","bullets":["Upfront payment of $150,000 plus potential $45M in milestone payments if first FDA approval for non-rare pediatric indication.","AUG assumes up to $150K of liabilities and all costs from transaction date; closing expected Q4 2023.","CEO says divestiture refocuses on immunology assets, improves cash flow and reduces resource utilization on non-core.","Contingent payments of up to 20% of proceeds from any sale of priority review voucher granted by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-032021","json":"https://secwatch.observer/filing/0001628280-23-032021.json","markdown":"https://secwatch.observer/filing/0001628280-23-032021.md","text":"https://secwatch.observer/filing/0001628280-23-032021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/0001628280-23-032021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/avtx-20230911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:00:26.883859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb499ea4cd6cbb740ae927d005fd16aa95f36897","claim":"Avalo Therapeutics, Inc. entered into Asset Purchase Agreement with AUG Therapeutics, LLC valued at an upfront payment of $150,000 (effective 2023-09-11).","evidence_excerpt":"On September 11, 2023, Avalo Therapeutics, Inc. (the \" Company \") entered into an Asset Purchase Agreement (the \" Purchase Agreement \") with AUG Therapeutics, LLC","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/0001628280-23-032021-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"AUG Therapeutics, LLC"},{"label":"Value","value":"an upfront payment of $150,000"},{"label":"Effective","value":"2023-09-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}